The US Food and Drug Administration (FDA) has approved Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are ...

Research presented at ASH 2024 has shed new light on treatment strategies for mantle cell lymphoma and follicular lymphoma.

Life expectancy in the United States is worse than in many other countries and declined from 1990 to 2021, data suggest.

Trial results presented at the ASH Annual Meeting 2024 could prompt changes in the treatment of CLL and SLL, experts say.

(HealthDay News) — The incidence of distant-stage breast cancer at presentation is increasing in the United States, according to a study published in Radiology. Researchers examined trends in ...

In a phase 3 trial, ASCT did not improve survival outcomes in patients with MCL who had an MRD-negative CR after induction.

Pirtobrutinib improved outcomes over investigator’s choice of treatment in patients with CLL/SLL previously treated with a cBTKi.

In most countries, prostate cancer incidence and mortality rates decreased or were stable in the most recent 5-year period evaluated.

Gaps between healthspan and lifespan are increasing around the world, and the United States has the largest gap, researchers found.

The 36-month overall survival rate was 74% in the belantamab mafodotin arm and 60% in the daratumumab arm. Belantamab ...

This page includes links to articles highlighting the top genitourinary cancer research published on Cancer Therapy Advisor in 2024.

Paclitaxel-based and nab-paclitaxel-based chemotherapy produced similar 5-year outcomes in patients with high-risk, HR+, HER2- early breast cancer.